FDA: Leiner should have recalled drugs

Over-the-counter drug maker Leiner Health Products is under the FDA gun. Regulators say the company falsified quality-control test results and failed to recall drugs it should have taken off the market. Leiner officials blamed the problems on rogue employees who've since been terminated.

The FDA swept into Leiner's South Carolina plan in January on the strength of employee complaints. The agency is still trying to determine whether the company committed criminal violations, according to an affidavit filed in a nearby federal court.

- check out this article from the Charlotte Observer

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

Suggested Articles

The new Community trial will first test Amgen's Otezla, Takeda's Takhzyro and UCB's zilucoplan in hospitalized patients.

Indivior faces a new lawsuit from RB, its former parent company, over a scheme to market opioid addiction therapy Suboxone Film.

A new FDA effort brings cancer drug labels to life in videotaped panels with experts, debuting its first episode on Seagen's MBC med Tukysa.